← All trials

NCT00840801

Phase 3Interventional

Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.

View on ClinicalTrials.gov ↗

Timeline

Start date
Feb 1, 2009
Primary completion
May 1, 2009
Completion date
Aug 1, 2010
First posted
Last posted
Enrollment
302
Arms / groups
2 / —
Source
AACT · pre-existing

Sponsors

  • PfizerLead sponsor
  • BaxaltaOverall official - principal investigator

Drugs studied

Indications studied

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.